Co-Delivery of CPT-11 and Panobinostat with Anti-GD2 Antibody Conjugated Immunoliposomes for Targeted Combination Chemotherapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Nov 4

PMID 33142721

Citations 10

Authors

Gils Jose

Yu-Jen Lu

Jung-Tung Hung

Alice L Yu

Jyh-Ping Chen

Affiliations

Soon will be listed here.

Abstract

The consistent expression of disialoganglioside GD2 in neuroblastoma tumor cells and its restricted expression in normal tissues open the possibility to use it for molecularly targeted neuroblastoma therapy. On the other hand, immunoliposomes combining antibody-mediated tumor recognition with liposomal delivery of chemotherapeutics have been proved to enhance therapeutic efficacy in brain tumors. Therefore, we develop immunoliposomes (ImmuLipCP) conjugated with anti-GD2 antibody, for targeted co-delivery of CPT-11 and panobinostat in this study. U87MG human glioma cell line and its drug resistant variant (U87DR), which were confirmed to be associated with low and high expression of cell surface GD2, were employed to compare the targeting efficacy. From in vitro cytotoxicity assay, CPT-11 showed synergism drug interaction with panobinostat to support co-delivery of both drugs with ImmuLipCP for targeted synergistic combination chemotherapy. The molecular targeting mechanism was elucidated from intracellular uptake efficacy by confocal microscopy and flow cytometry analysis, where 6-fold increase in liposome and 1.8-fold increase in drug uptake efficiency was found using targeted liposomes. This enhanced intracellular trafficking for drug delivery endows ImmuLipCP with pronounced cytotoxicity toward U87DR cells in vitro, with 1.6-fold increase of apoptosis rate. Using xenograft nude mice model with subcutaneously implanted U87DR cells, we observe similar biodistribution profile but 5.1 times higher accumulation rate of ImmuLip from in vivo imaging system (IVIS) observation of Cy5.5-labelled liposomes. Taking advantage of this highly efficient GD-2 targeting, ImmuLipCP was demonstrated to be an effective cancer treatment modality to significantly enhance the anti-cancer therapeutic efficacy in U87DR tumors, shown from the significant reduced tumor size in and prolonged survival time of experiment animals as well as diminished expression of cell proliferation and enhanced expression of apoptosis marker proteins in tumor section.

Citing Articles

LINC01094: A key long non-coding RNA in the regulation of cancer progression and therapeutic targets.

Yi Q, Zhu G, Zhu W, Wang J, Ouyang X, Yang K Heliyon. 2024; 10(18):e37527.

PMID: 39309878 PMC: 11415682. DOI: 10.1016/j.heliyon.2024.e37527.

Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy.

Sun L, Li Z, Lan J, Wu Y, Zhang T, Ding Y Front Pharmacol. 2024; 15:1389922.

PMID: 38831883 PMC: 11144913. DOI: 10.3389/fphar.2024.1389922.

Applications of Nanomedicine in Brain Tumor Therapy: Nanocarrierbased Drug Delivery Platforms, Challenges, and Perspectives.

Verma R, Rao L, Kumar H, Bansal N, Deep A, Parashar J Recent Pat Nanotechnol. 2023; 19(1):99-119.

PMID: 37937554 DOI: 10.2174/0118722105244482231017102857.

Biology of GD2 ganglioside: implications for cancer immunotherapy.

Machy P, Mortier E, Birkle S Front Pharmacol. 2023; 14:1249929.

PMID: 37670947 PMC: 10475612. DOI: 10.3389/fphar.2023.1249929.

Cetuximab-Conjugated Magnetic Poly(Lactic-co-Glycolic Acid) Nanoparticles for Dual-Targeted Delivery of Irinotecan in Glioma Treatment.

Dash B, Lu Y, Luo S, Chen J Materials (Basel). 2023; 16(16).

PMID: 37629816 PMC: 10456415. DOI: 10.3390/ma16165526.

References

Garcia-Carbonero R, Supko J . Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002; 8(3):641-61. View

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View

Rai Y, Pathak R, Kumari N, Sah D, Pandey S, Kalra N . Mitochondrial biogenesis and metabolic hyperactivation limits the application of MTT assay in the estimation of radiation induced growth inhibition. Sci Rep. 2018; 8(1):1531. PMC: 5784148. DOI: 10.1038/s41598-018-19930-w. View

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Pagnan G, Stuart D, Pastorino F, Raffaghello L, Montaldo P, Allen T . Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst. 2000; 92(3):253-61. DOI: 10.1093/jnci/92.3.253. View

Noble G, Stefanick J, Ashley J, Kiziltepe T, Bilgicer B . Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2013; 32(1):32-45. DOI: 10.1016/j.tibtech.2013.09.007. View

Li X, Tang W, Xie H, Liu S, Song X, Xiao Y . The efficacy of RGD modified liposomes loaded with vinorelbine plus tetrandrine in treating resistant brain glioma. J Liposome Res. 2017; 29(1):21-34. DOI: 10.1080/08982104.2017.1408649. View

Attia M, Anton N, Wallyn J, Omran Z, Vandamme T . An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019; 71(8):1185-1198. DOI: 10.1111/jphp.13098. View

Chen T, Su S, Fry D, Liebes L . Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer. 2003; 97(9 Suppl):2363-73. DOI: 10.1002/cncr.11307. View

10.

Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase E, Allen T . Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 2003; 63(1):86-92. View

11.

Drummond D, Noble C, Hayes M, Park J, Kirpotin D . Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci. 2008; 97(11):4696-740. DOI: 10.1002/jps.21358. View

12.

Senapati S, Mahanta A, Kumar S, Maiti P . Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018; 3:7. PMC: 5854578. DOI: 10.1038/s41392-017-0004-3. View

13.

Wu M, Yan B, Humerickhouse R, Dolan M . Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res. 2002; 8(8):2696-700. View

14.

Nakatsu S, Kondo S, Kondo Y, Yin D, Peterson J, Kaakaji R . Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol. 1997; 39(5):417-23. DOI: 10.1007/s002800050592. View

15.

Lypova N, Lanceta L, Gibson A, Vega S, Garza-Morales R, McMasters K . Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy. Cancers (Basel). 2019; 11(5). PMC: 6563125. DOI: 10.3390/cancers11050684. View

16.

Andreu-Vieyra C, Berenson J . The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol. 2014; 5(6):197-210. PMC: 4250267. DOI: 10.1177/2040620714552614. View

17.

Gawley M, Almond L, Daniel S, Lastakchi S, Kaur S, Detta A . Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme. J Control Release. 2020; 324:1-16. DOI: 10.1016/j.jconrel.2020.05.012. View

18.

Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A . Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018; 10(2). PMC: 6027495. DOI: 10.3390/pharmaceutics10020057. View

19.

Yuan F, Leunig M, Huang S, Berk D, Papahadjopoulos D, Jain R . Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994; 54(13):3352-6. View

20.

Xu X, Pan X, Wang T, Wang J, Yang B, He Q . Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies. Acta Pharmacol Sin. 2020; 42(2):171-178. PMC: 8027849. DOI: 10.1038/s41401-020-0416-4. View